Buprenorfina transdérmica | 05 JUL 10
Innovación en el manejo del dolor
El dolor es síntoma prevalente en 30% de los pacientes con cáncer al ser diagnosticados, y en más del 70% de aquéllos con enfermedades metastásica avanzada.
Autor: Dr. José de Jesús Villafaña, Dra. María Luisa Perez, Dr. Julio Delgado, Dra. Verónica Rayo; Instituto Mexicano del Seguro Social Revista Dolor Año 7/ Vol. IV/ 2010
INDICE:  1. Desarrollo | 2. Bibliografía

1. Mercadante S. Buprenorfina y dolor relacionado con el cáncer. Buprenorfina, un analgésico excepcional. Farmacología y Aplicación Clínica. Ed. Keith Budd and Robert Raffa 2006. Cap 7.

2. Budd K. High Dose Buphrenorphine for postoperative analgesia. Anaesthesia 1981;36:900-903.

3. Budd K. Buphrenorphine and the transdermal system. The ideal match in pain management. Int J Clin Prac 2003;S 133:9-14.

4. Budd K. Experience with partial agonists in the treatment of cancer pain. In: Doyle D (Ed). Opioid in the Treatment of Cancer Pain. London, Royal Society of Medicine, 1990:51-55.

5. Walsh S, Preston KL, Bigelow GE, Stitzer ML. Acute administration of buprenorphine in humans: Partial agonist and lockade effects. J Pharmacol Exp Ther 1995;274:361-372.

6. Koegel B, Christoph T, Strassburger W,Friderichs E. Interaction of μ opiod receptor agonists and antagonist with the analgesic effect of Buprenorphine in mice. Eur J Pain 2005:599-611.

7. Lewis JW. Buprenorphine. Drug Alcohol Depend 1985;14:363-372. http://dx.doi.org

8. Rance MJ, Shillingford JS. The role of the gut in the metabolism of strong analgesics. Biochem Pharmacol 1976;25:735-741.

9. Rance MJ Shilingford JS. The metabolism of phenolic opiates by rat intestine. Xenobiotica 1977;67:529-536.

10. Bartleson JD. Evidence for and against the use of opioid analgesics for chronic non malignant low back pain: a review. Pain Med 2002;3:260-271.

11. Kalso E. Route of opioid administration: does it make a difference? In: Kalso E, McQuay Hj, Wiesenfeld- Hallin Z, editors. Opioid sensitivity of chronic non cancer pain. Progress in pain research and management, vol. 14. IASP Press, Seattle, 1999:117.

12. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotesis derived from studies of opioid infusions. Pain 1990;43:273-286.

13. Robinson SE. Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction. CNS Drug Rev 2002;8:377-390.

14. Christoph T, Kogel B, Schiene K, Meen M, de Vry J, Friderichs E. Broad analgesic profile of buprenophine in rodent models of acute and chronic pain. Eur J Pharmacol 2005;507:87-98.

15. Staats PS, Johnson, RE. New perspectives on the pharmacology of opioids and their use in chronic pain. Prog Anaesthesiol 2002;16:235-249.

16. Daha A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 2005;94:825-834.

17. Zaki PA, Keith DE Jr, Brine GA, Carroll FI, Evans CJ. Ligand-induced changes in surface -opioid receptor number: relationship to G protein activation? J Pharmacol Exper Ther 2000;292:1127-1134.

18. Budd K. Immunosuppressive effects induced by opioid analgesics. Int Monit Reg Anaest Pain Ther 2000;14: 3-7.

19. Poulsen Nautrup B, Nuijten MJC. Retrospective analysis of drug utilization patterns in cancer and non-cancer patients treated with transdermal buprenorphine and transdermal fentanyl (abstract). Value Health 2005;8:411-412 (PPN6).

20. Evans HC, Easthope SE. Transdermal Buprenorphine. Drugs 2003;63:1999-2010.

21. Heel RC, Brogden RN, Speight TM, Avery GS. Buprenorphine: A review of its pharmacological properties and therapeutic efficacy. Drugs 1979; 17:81-110.

22. Jasinki JR, Pevnik JS, Grifith JG. Human pharmacology and abuse potencial of the analgesic buprenorphine. Arch Gen Psychiat 1978;35:501-516.

23. Strain EC, Stizer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am Psychiatry 1994;151:1025-1030.

24. Walsh SL, Preston KL, Stizer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceding effects at high doses. Clin Pharmacol Ther. 1994;55:569-580.

25. Bullinham RES, McQuay HJ, Moore A, Bennett MRD. Buprenorphine kinetics. Clin Pharmacol Ther 1980;28:667-672.

26. Fecho K, Maslonek KA, Dykstra LA, Lysle DT. Evidence for sympathetic and adrenal involvement in the immunomodulatory effects of acute morphine treatment in rats. J Pharm Exp Ther 1996;227:633-645.

27. Sacerdote P, Manfredi B, Mantegazza P, Panerai AE. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol 1997;121:834-840.

28. Van Loveren, Gianotten N, Hendriksen CF, Schuurman HJ, Van der Laan JW. Assessment of immunotoxicity of buprenorphine. Lab Anim 1994;28:355-363.



Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí